BioSenic S.A.
BIOS.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.09 | 0.15 |
| FCF Yield | 0.00% | -41.37% | -16.60% | -91.53% |
| EV / EBITDA | -5.93 | -5.41 | -14.83 | -9.50 |
| Quality | ||||
| ROIC | -645.75% | -119.41% | -8.59% | -20.37% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 316.35% |
| Cash Conversion Ratio | 0.47 | 0.12 | 0.82 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 20.29% | -33.36% | – |
| Free Cash Flow Growth | 100.00% | -81.20% | 85.26% | 19.68% |
| Safety | ||||
| Net Debt / EBITDA | -5.65 | -4.18 | -9.72 | 6.93 |
| Interest Coverage | -4.93 | -1.18 | -8.34 | -11.11 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.01 |
| Cash Conversion Cycle | 0.00 | 224.51 | -9,035.39 | 62,739.05 |